CareDx, Inc (CDNA) Report Analysis
Corporate Events
CareDx, Inc Presents at Annual Onco Cell Therapy Summit, Jun-29-2022 11:55 AM
2022-06-28 15:19:00
CareDx, Inc Presents at Annual Onco Cell Therapy Summit, Jun-29-2022 11:55 AM. Venue: Boston, United States. Speakers: Ashish Kothari, VP, Clinical Development, CellTransplant Therapy.
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Caredx, Inc
2022-06-24 13:11:00
The law firm of Kessler Topaz Meltzer & Check, LLP informed investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against CareDx Inc. The action charges CareDx with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of CareDx’s materially misleading statements and omissions to the public, CareDx’s investors have suffered significant losses. LEAD PLAINTIFF DEADLINE:JULY 22, 2022. CLASS PERIOD: FEBRUARY 24, 2021 through MAY 5, 2022. On February 24, 2021, CareDx reported a 51% year-over-year increase in total revenue, with testing services revenue increasing from $104.6 million in 2019 to $163.5 million in 2020. CareDx presented the testing services segment as CareDx’s “growth driver” for which “demand continued unabated.” Moreover, the CareDx described its testing services segment as having “a winning formula” that would allow it to capture a massive total addressable market. On October 28, 2021, CareDx filed its quarterly report for the third quarter of 2021 on a Form 10-Q which revealed that it had received several inquiries from multiple governmental agencies relating to its business and practices, including: (1) a civil investigative demand (CID) from the U.S. Department of Justice in connection with its False Claims Act investigation; (2) a subpoena from the SEC in relation its investigation relating to issues identified in the CID and certain of CareDx’s accounting and public reporting practices; and (3) an information request from an unnamed state regulatory agency. Following this news, the price of CareDx shares declined more than 27%, from a closing price of $70.34 per share on October 28, 2021, to a closing price of $51.00 per share on October 29, 2021. Then, after the markets closed on May 5, 2022, CareDx shocked the market when it announced its results for the first quarter of 2022. CareDx reported testing services revenue that fell well short of analysts’ expectations and yet another decline in average sales price in which CareDx’s average price declined by approximately 4.9% versus the last quarter of 2021, or what one analyst described as “another big deterioration in price.” Following this news, the price of CareDx stock declined 18.5%, from a closing price of $31.66 per share on May 5, 2022, to a closing price of $25.87 per share on May 6, 2022.
CareDx, Inc Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 02:00 PM
2022-06-03 08:47:00
CareDx, Inc Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 02:00 PM. Venue: Marriott Marquis, New York City, New York, United States.
CareDx, Inc - Special Call
2022-06-02 11:01:00
CareDx, Inc - Special Call
Saxena White P.A. Files New Securities Fraud Class Action Against CareDx, Inc
2022-05-23 22:03:00
Saxena White P.A. has filed a securities fraud class action lawsuit in the United States District Court for the Northern District of California against CareDx Inc. and certain of its executive officers (collectively, “Defendants”). The Class Action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and U.S. Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder on behalf of all persons or entities that purchased CareDx common stock between February 24, 2021 and May 5, 2022, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Saxena White is captioned: Plumbers & Pipefitters Local Union #295 Pension Fund v. CareDx Inc., et al., No. 3:22-cv-03023 (N.D. Cal.) The Class Action alleges that, during the Class Period, Defendants misled investors and/or failed to disclose that: (1) Defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the RemoTraC service; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company’s testing services revenue reported throughout the Class Period artificially inflated; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The truth began to emerge on October 28, 2021, when CareDx filed its quarterly report for the third quarter of 2021 on Form 10-Q with the SEC. Under the heading “United States Department of Justice and United States Securities and Exchange Commission Investigation,” the Company revealed for the first time that CareDx was the subject of at least three government investigations related to its “accounting and public reporting practices.” In response to this news, CareDx’s stock price fell 27%, from a closing price of $70.34 per share on October 28, 2021, to a closing price of $51.00 per share on October 29, 2021.
CareDx, Inc. Announces Executive Changes
2022-05-23 11:31:00
CareDx Inc. announced that Ankur Dhingra, the Chief Financial Officer notified the Company of his intent to resign from the Company, effective as of the end of the day on May 25, 2022, to pursue another career opportunity. The Company has launched a formal search process to identify Mr. Dhingra’s successor with the assistance of an established search firm. In connection with Mr. Dhingra’s resignation, on May 20, 2022, the Company entered into a consulting agreement with Mr. Dhingra (the “Consulting Agreement”). Pursuant to the Consulting Agreement, commencing May 27, 2022, Mr. Dhingra will provide up to 20 hours of consulting services to the Company per month for an initial period of four months (the “Initial Period”), which, subject to the agreement of the Company and Mr. Dhingra, may be extended for an additional two month period, for a total consulting period of up to six months. The Company appointed Abhishek Jain, age 46, as the Company’s Interim Chief Financial Officer, effective May 26, 2022. Upon commencement of his appointment, Mr. Jain will assume the duties of the Company’s principal financial officer and principal accounting officer until such time as his successor is appointed, or until his earlier resignation or removal.
Natera Drops One of Their Two Patents Originally Asserted Against CareDx, Inc
2022-05-17 11:00:00
CareDx Inc. announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents that are variations of the original patent that Natera continues to assert against CareDx. CareDx believes all the recycled patents asserted against CareDx are invalid and are not infringed. These IP filings follow a notable jury trial from March of this year that found Natera intentionally engaged in false advertising in promotion of their Prospera test. The jury unanimously awarded CareDx $44.9 million in punitive and compensatory damages. The evidence at trial, including emails from the most senior levels of Natera and its CEO, showed a systematic approach to mislead transplant clinicians.
CareDx, Inc Provides Revenue Guidance for the Full Year 2022
2022-05-05 20:01:00
CareDx Inc. provided revenue guidance for the full year 2022. For the year, the company has reiterated its revenue expectations in the range of $330 million to $350 million.
CareDx, Inc. Validates Clinical Performance of AlloMap Kidney to Comprehensively Assess Transplant Rejection
2022-05-05 11:00:00
CareDx Inc. announced the publication of new data demonstrating that AlloMap Kidney gene-expression profiling predicts the probability of allograft rejection for both antibody-mediated rejection (ABMR) and T cell-mediated rejection (TCMR). The new data, published in Biomarkers in Medicine, combining multiple data sets, including the multi-center, prospective OKRA (Outcomes of KidneyCare in Renal Allografts) study (NCT03326076), shows that AlloMap Kidney can reliably discriminate rejection from quiescence in kidney transplant patients with a negative predictive value of 95%. The results are consistent with previously published clinical validation study results. CareDx is an innovator in multimodality transplant solutions. HeartCare, which includes AlloSure and AlloMap for heart transplant patients, is utilized by the majority of heart transplant centers in the United States. CareDx is bringing its deep expertise in multimodality care to the kidney transplant community with the eventual commercialization of KidneyCare.
CareDx, Inc Presents at Allogeneic Cell Therapies Summit Virtual Conference 2022, May-10-2022 12:00 PM
2022-05-05 06:06:00
CareDx, Inc Presents at Allogeneic Cell Therapies Summit Virtual Conference 2022, May-10-2022 12:00 PM. Venue: Boston, Massachusetts, United States. Speakers: Ashish Kothari, VP, Cell Transplant Therapy.
CareDx, Inc - Shareholder/Analyst Call
2022-05-02 17:16:00
AGM
CareDx, Inc, Annual General Meeting, Jun 15, 2022
2022-05-02 17:16:00
CareDx, Inc, Annual General Meeting, Jun 15, 2022, at 10:00 Pacific Standard Time. Agenda: To elect three Class II directors to serve until the 2025 annual meeting of stockholders or until their successors are duly elected and qualified; to ratify the appointment of Deloitte & Touche LLP as independent registered public accounting firm for our fiscal year ending December 31, 2022; to approve, on an advisory basis, the compensation of named executive officers; and to conduct any other business properly brought before the Annual Meeting and any adjournments or postponements thereof.
CareDx, Inc Extends Artificial Intelligence Leadership to Heart Transplantation
2022-04-28 11:00:00
CareDx Inc. announced that through its ongoing partnership with OrganX it plans to expand its HeartCare multimodality portfolio with a new artificial intelligence (AI) prognostic for cardiac allograft vasculopathy (CAV). CareDx’s new AI prognostic for CAV helps to stratify patients based on their risk of developing CAV, a leading cause of heart transplant failure.1,2 When used together with AlloMap® gene-expression profiling to assess immune quiescence and AlloSure® donor-derived cell-free DNA to assess organ injury, this new information about a patient’s risk for CAV and projected outcome has the potential to enable a more precise and personalized approach to interventions aimed at improving long-term heart transplant outcomes.
CareDx, Inc, Q1 2022 Earnings Call, May 05, 2022
2022-04-27 21:27:00
CareDx, Inc, Q1 2022 Earnings Call, May 05, 2022
CareDx, Inc to Report Q1, 2022 Results on May 05, 2022
2022-04-27 20:01:00
CareDx, Inc announced that they will report Q1, 2022 results After-Market on May 05, 2022
Caredx Demonstrates Potential of Alloheme and Allocell for Allogeneic Cell Transplant and Therapy Monitoring
2022-04-22 11:00:00
CareDx Inc. announced the presentation of new data during the Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR being held on April 23-26 in Salt Lake City, Utah, highlighting the capabilities of AlloHeme™ and AlloCell for allogeneic cell transplant and therapy monitoring. CareDx will also share information about its OTTR® Patient Management Software that has recently been validated to SMART (Substitutable Medical Applications, Reusable Technologies) on FHIR (Fast Healthcare Interoperability Resource) standards and is available for customer use. CareDx is advancing its product pipeline with new scientific innovations for blood cancers that will help monitor treatment response after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) using AlloHeme and after allogeneic cell therapy using AlloCell.
CareDx, Inc Presents at ISHLT 2022 - International Society of Heart and Lung Transplantation Meeting/Conference, Apr-27-2022
2022-04-20 11:00:00
CareDx, Inc Presents at ISHLT 2022 - International Society of Heart and Lung Transplantation Meeting/Conference, Apr-27-2022 . Venue: Boston, Massachusetts, United States.
CareDx, Inc has filed a Follow-on Equity Offering in the amount of $200 million.
2022-04-14 00:00:00
CareDx, Inc has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Common stock Security Type: Common Stock Transaction Features: At the Market Offering
CareDx, Inc has filed a Shelf Registration in the amount of $83.888583 million.
2022-04-13 00:00:00
CareDx, Inc has filed a Shelf Registration in the amount of $83.888583 million. Security Name: Common Stock Securities Offered: 2,250,834 Transaction Features: ESOP Related Offering
CareDx, Inc Presents at Transplant Management Forum, Apr-11-2022
2022-04-11 11:00:00
CareDx, Inc Presents at Transplant Management Forum, Apr-11-2022 . Venue: Phoenix, United States.
United Network For Organ Sharing, Transplant Management Forum, Apr 11, 2022 through Apr 13, 2022
2022-04-04 15:56:00
United Network For Organ Sharing, Transplant Management Forum, Apr 11, 2022 through Apr 13, 2022. Venue: Phoenix, United States.
Hanson Wade Limited, Allogeneic Cell Therapies Summit Virtual Conference 2022, May 09, 2022 through May 12, 2022
2022-03-31 14:21:00
Hanson Wade Limited, Allogeneic Cell Therapies Summit Virtual Conference 2022, May 09, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.
CareDx, Inc has filed a Shelf Registration in the amount of $1.430682 million.
2022-03-30 00:00:00
CareDx, Inc has filed a Shelf Registration in the amount of $1.430682 million. Security Name: Common Stock Securities Offered: 674,850 Transaction Features: ESOP Related Offering
CareDx, Inc - Special Call
2022-03-29 11:00:00
CareDx, Inc - Special Call
The International Society for Heart and Lung Transplantation, ISHLT 2022 - International Society of Heart and Lung Transplantation Meeting/Conference, Apr 27, 2022 through Apr 30, 2022
2022-03-20 04:56:00
The International Society for Heart and Lung Transplantation, ISHLT 2022 - International Society of Heart and Lung Transplantation Meeting/Conference, Apr 27, 2022 through Apr 30, 2022. Venue: Boston, Massachusetts, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
Kisaco Research, Annual Onco Cell Therapy Summit, Jun 29, 2022 through Jun 30, 2022
2021-12-26 17:53:00
Kisaco Research, Annual Onco Cell Therapy Summit, Jun 29, 2022 through Jun 30, 2022. Venue: Boston, United States.
CareDx, Inc Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes
2021-12-16 12:00:00
CareDx Inc. announced the enrollment of the first patient in the multicenter, observational, prospective ALAMO registry to improve lung transplant patient care. The AlloSure Lung Assessment and Metagenomic Outcomes (ALAMO) registry will enroll 1,000 patients from lung transplant centers across the United States. The registry will follow patients using LungCare, which includes commercially available AlloSure® Lung, and research use of AlloMap® Lung, AlloID, and other complementary tests. AlloSure is a donor-derived cfDNA test which identifies organ injury, AlloMap is a gene expression test which identifies immune quiescence, and AlloID is a metagenomic infectious disease test which identifies more than 100 pathogens specific to organ transplant patients. The ALAMO registry will examine CareDx’s LungCare to inform biopsy and treatment decisions following lung transplantation. Its primary endpoints are three-year survival without chronic lung allograft dysfunction (CLAD) and three-year, severe infection-free survival.
CareDx, Inc Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021
2021-11-22 15:06:00
CareDx, Inc Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.
CareDx Enrolls First Patients in the Largest Digital Study in Transplant Using AlloCare to Assess Patient Outcomes
2021-11-18 12:00:00
CareDx Inc. announced the enrollment of the first patients in what will be the largest ever digital study measuring the impact of AlloCare™, a tech-enabled mobile health app, on organ transplant patient outcomes. The TEAMMATE (Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient) study will enroll 4,000 patients from more than 100 transplant centers nationwide as part of a prospective, randomized, controlled, multicenter study spanning kidney, heart, lung, and liver transplantation. Half of the participants will be enrolled in the study arm and half in the control arm. The study arm will have patients trained for regular use of the AlloCare mobile health app. The control arm will maintain the center’s standard of care. The primary endpoint will be 90-day readmission rates. The secondary endpoints will include medication adherence, blood pressure management, organ rejection at 3, 6, and 12 months, and patient satisfaction levels. AlloCare is a patient management app that helps transplant recipients precisely manage their medications, schedule their lab work, track their blood pressure and other vital metrics, view their AlloSure® and other test results, and connect with other transplant recipients. AlloSure is a non-invasive transplant diagnostic tool that measures donor-derived cell-free DNA (dd-cfDNA) levels released into the blood stream to indicate potential, post-transplant allograft injury.
CareDx, Inc Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:15 PM
2021-11-18 04:07:00
CareDx, Inc Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:15 PM.
CareDx, Inc (NasdaqGM:CDNA) acquired MedActionPlan®.
2021-11-10 00:00:00
CareDx, Inc (NasdaqGM:CDNA) acquired MedActionPlan® on November 10, 2021. CareDx, Inc (NasdaqGM:CDNA) completed the acquisition of MedActionPlan® on for $3.5 million November 10, 2021. CareDx acquired MedActionPlan with a combination of cash consideration paid upfront and contingent consideration with a fair value of $3.5 million.
CareDx, Inc. Announces Management Changes
2021-11-01 20:01:00
CareDx Inc. announced that the company has completed its transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer. Concurrent with the appointment of Dr. Seeto as President and Chief Executive Officer of CareDx in November 2020, Dr. Maag had agreed to serve as Executive Chairman of the company’s Board of Directors to facilitate an orderly transition. Now that this transition is complete, Dr. Maag will step down as Executive Chairman but will continue to serve the company as a member of its Board of Directors. Michael D. Goldberg, CareDx’s lead independent Director, will resume his prior role as independent Chair, a position he previously held from 2011 to 2019.
CareDx, Inc. Announces Chief Executive Officer Changes
2021-11-01 20:01:00
CareDx Inc. announced that the company has completed its transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer.
CareDx, Inc Provides Earnings Guidance for the Full Year 2021
2021-10-28 20:01:00
CareDx Inc. provided earnings guidance for the full year 2021. For the year, the company expected revenue to be in the range of $290 million to $293 million (previously $280 million to $290 million).
CareDx and Eledon Pharmaceuticals Announces Collaborative Research Agreement
2021-10-19 11:00:00
CareDx, Inc. and Eledon Pharmaceuticals, Inc. announced a collaborative research agreement to use AlloSure to help assess the efficacy of Eledon’s investigational AT-1501 in the prevention of rejection in upcoming renal transplantation trials. In July of this year, Eledon announced that it had received approval from Health Canada to commence human trials of AT-1501 in renal transplantation. The study will be a multicenter, open label trial, in 6 to 12 subjects, to evaluate the safety, efficacy and pharmacokinetics of AT-1501 in de novo kidney transplant recipients. Eledon anticipates initiating the trial in the fourth quarter of this year with interim data read-outs beginning in late 2022.
CareDx, Inc to Report Q3, 2021 Results on Oct 28, 2021
2021-10-14 20:01:00
CareDx, Inc announced that they will report Q3, 2021 results After-Market on Oct 28, 2021
CareDx, Inc, Q3 2021 Earnings Call, Oct 28, 2021
2021-10-14 20:01:00
CareDx, Inc, Q3 2021 Earnings Call, Oct 28, 2021
Allosure Launches for Lung Transplant Patients
2021-10-12 14:18:00
CareDx Inc. announced the commercial launch of AlloSure Lung to coincide with the CHEST 2021 Meeting starting on October 16. AlloSure, which is commercially available and broadly used in kidney and heart transplantation, will now be widely available for use in lung transplantation. CareDx is working with payers to obtain coverage for AlloSure Lung across the payer landscape. AlloSure Lung is already covered by multiple private payers, and is meeting an incredible unmet need for lung transplant patients. Lung transplantation has one of the lowest median survivals of any solid organ transplant, with a 5-year survival rate of 53%. Lung transplant patients have an increased incidence of Chronic Lung Allograft Dysfunction (CLAD), which is a form of chronic organ rejection. These patients are not only on more intensive immunosuppressive regimens to forestall rejection, but also have an increased frequency of infectious complications due to these higher immunosuppression levels and contact of the lung graft with the outside environment. With the COVID pandemic, the need for home-based, noninvasive tools to monitor lung transplant patients became more critical. CareDx made AlloSure Lung available to centers through the RemoTraC mobile phlebotomy service to support these high-risk patients. Three clinical validation studies have been published to show the clinical benefit of AlloSure Lung in managing patient care with data from 11 centers across 155 patients, where 61 experienced a rejection episode.
CareDx, Inc Presents at BioFuture, Oct-05-2021
2021-09-30 19:39:00
CareDx, Inc Presents at BioFuture, Oct-05-2021 . Venue: The Lotte Palace Hotel, New York City, New York, United States.
CareDx, Inc Names Art Torres to Board of Directors
2021-09-15 12:00:00
CareDx Inc. announced the appointment of Art Torres to its Board of Directors. Torres serves as vice chair of the governing board of the California Institute for Regenerative Medicine as well as a member of the University of California Board of Regents and the Covered California board overseeing Obamacare. He is also the vice chair on the board of One Legacy, an organ transplant foundation based in Southern California, and has been a vocal advocate for organ transplant awareness in communities of color.
CareDx, Inc Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM
2021-09-02 11:09:00
CareDx, Inc Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.
CareDx, Inc. to Present Six Abstracts on AlloSeq cfDNA and launch of AlloSeq cfDNA Research Service at European Society of Organ Transplantation (ESOT) 2021 conference
2021-08-26 11:00:00
CareDx Inc. announced that will showcase leadership in global transplant patient care with six abstracts on AlloSeq cfDNA and the launch of AlloSeq cfDNA Research Service at European Society of Organ Transplantation (ESOT) 2021 conference, August 29 to September 1 in Milan, Italy and virtually. AlloSeq cfDNA is a next generation sequencing based kit to detect donor-derived cfDNA (dd-cfDNA) and can be used locally in a transplant center lab to generate results in less than 24 hours. The newly launched AlloSeq cfDNA Research Service is a solution for centers outside of the US that want to send out dd-cfDNA testing for research use only, and AlloSeq cfDNA will be run out of CareDx’s Stockholm site. CareDx will launch AlloSeq cfDNA Research Service and showcase the latest data on AlloSeq cfDNA at an ESOT symposium titled, “Changing the Transplant Care Paradigm: Advanced Strategies for Allograft Surveillance.” The symposium will be held live and streamed virtually on ESOT’s platform on Sunday, August 29 from 6:00-7:30 PM CET. Featured speakers include: Fritz Diekmann, MD, PhD, Universitat de Barcelona, Hospital Clínic de Barcelona; Ioannis N. Boletis, MD, PhD, Laiko General Hospital, National & Kapodistrian University of Athens; Berta Saez-Gimenez, MD, PhD, Hospital Universitari Vall d'Hebrón; and Kiran Khush, MD, Stanford University School of Medicine. AlloSeq cfDNA data will also be presented in six oral presentations or posters at ESOT: Pitfalls in the detection of donor-derived cell-free DNA in transplant recipients; Presented by Dr. Jeroen Verhoeven on August 30; 16:45 – 18:15. Comparing methods for donor-derived cell-free DNA quantification in plasma and urine from kidney and liver transplant recipients; presented by Dr. Nicholas Kueng on August 30; 16:45 – 18:15. Monitoring kidney graft injury by measuring donor-derived cell-free DNA (dd-cfDNA); Presented by Dr. Emilio Rodrigo on September 1; 08:00 – 09:30. Prospective evaluation of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients with indication biopsy; Presented by Dr. Louise Benning on September 1; 08:00 – 09:30. Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients; presented by Dr. Katharina Mayer on September 1; 10:00 – 11:30. Prospective assessment of graft recovery after kidney transplantation by means of donor-derived cell-free DNA; Poster Presentation.
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021
2021-08-24 20:29:00
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.
CareDx, Inc Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 03:20 PM
2021-08-23 03:08:00
CareDx, Inc Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 03:20 PM. Speakers: Ankur Dhingra, Chief Financial Officer, Reginald Seeto, President, CEO & Director.
CareDx, Inc has filed a Shelf Registration in the amount of $178.193367 million.
2021-08-06 00:00:00
CareDx, Inc has filed a Shelf Registration in the amount of $178.193367 million. Security Name: Common Stock Securities Offered: 2,111,546 Transaction Features: ESOP Related Offering
CareDx, Inc. Raises Revenue Guidance for the Full Year of 2021
2021-07-29 20:01:00
CareDx Inc. raised revenue guidance for the full year of 2021. For the period, the company expects revenue to be in the range of $280 million to $290 million.
CareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients
2021-07-26 11:00:00
CareDx Inc. announced the enrollment of the first patient in the Assessing Chimerism and Relapse of Bone marrow/HCT transplant using AlloHeme Testing (ACROBAT) study at the Cleveland Clinic in Ohio. The ACROBAT study is a prospective, multicenter, observational cohort study to evaluate the use of AlloHeme, a microchimerism tool to predict post-transplant relapse in patients with allogeneic hematopoietic cell transplants (HCT), also known as bone marrow or stem cell transplants. AlloHeme is an innovative testing solution that utilizes Next-Generation Sequencing technology to measure the relative amount of donor and recipient cells after a stem cell transplant. Monitoring for changes in chimerism over time using AlloHeme has the potential to significantly change patient surveillance and care in the underserved HCT patient population. Approximately 10,000 allogeneic stem cell transplants occur in the US each year as a potential cure for patients with late-stage cancer, such as acute myelogenous leukemia, acute lymphoid leukemia, and myelodysplastic syndrome. Chimerism testing has played an important role in monitoring donor engraftment in HCT patients. Predicting relapse using microchimerism measurement may establish a new standard in HCT patient surveillance and could enable earlier intervention and better outcomes.
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021
2021-07-22 09:08:00
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.
CareDx, Inc Announces Executive Changes
2021-07-20 20:55:00
Effective July 19, 2021, CareDx Inc. appointed Alex Johnson, age 47, as the Company’s Chief Business Officer and Head of Testing Services. There are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving the Company and Mr. Johnson. Mr. Johnson served as Senior Vice President, Products, Cell Therapy & Business Development of the Company since May 2020 and previously served as Vice President, Laboratory Solutions Business from August 2018 to May 2020 and Vice President, Finance from April 2018 to July 2018. Prior to joining the Company, Mr. Johnson was Chief Operating Officer of BioGraph 55, a venture-backed immuno-oncology drug development company that uses advanced imaging analytics and machine learning to capture clinically relevant content from the tumor microenvironment, from September 2015 to August 2018. From August 2014 to January 2015, Mr. Johnson served as President of Diadexus Inc. From 2009 to 2014, Mr. Johnson was with Novartis, with roles at Novartis Diagnostics, a global provider of blood screening solutions, and Novartis AG based in Basel, Switzerland where he led acquisitions in oncology and diagnostics. Prior to Novartis, Mr. Johnson worked at UBS Investment Bank in the Global Healthcare group. Mr. Johnson studied economics at Union College (NY) and received his M.B.A. in Finance from Columbia Business School. A petition of bankruptcy was filed by Diadexus Inc. in June 2016.
CareDx, Inc, Q2 2021 Earnings Call, Jul 29, 2021
2021-07-15 11:00:00
CareDx, Inc, Q2 2021 Earnings Call, Jul 29, 2021
CareDx, Inc to Report Q2, 2021 Results on Jul 29, 2021
2021-07-15 11:00:00
CareDx, Inc announced that they will report Q2, 2021 results After-Market on Jul 29, 2021
CareDx, Inc Appoints Hannah A. Valantine, M.D. as Class I Director
2021-07-01 20:21:00
On June 30, 2021, the board of directors of CareDx Inc. appointed Hannah A. Valantine, M.D. as a Class I director of the Company. Dr. Valantine’s service on the Board commenced on July 1, 2021. Dr. Valantine currently serves as Professor of Medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. From April 2014 to September 2020, Dr. Valantine served as Chief Officer for Scientific Workforce Diversity at the National Institutes of Health, and as a Senior Investigator in the Intramural Research Program at the National Heart, Lung, and Blood Institute. From November 2004 to April 2014, Dr. Valantine was Professor of Cardiovascular Medicine and the Senior Associate Dean for Diversity and Leadership at Stanford. In collaboration with her colleagues at Stanford, Dr. Valantine co-invented the technology for donor derived cell-free DNA for diagnosis of transplant rejection, which is currently licensed and used to monitor patients for early detection of acute rejection. Dr. Valantine also serves as Principal and Founder of HAV LLC, a consulting company for diversity, equity and inclusion that she founded in January 2021. Dr. Valantine has served as a member of the board of directors of Pacific Biosciences of California Inc. since June 2021.
CareDx, Inc.Transplant Patient App, Allocare, Expands Access to the Majority of Transplant Patients
2021-07-01 20:01:00
CareDx Inc. announced that AlloCare, the app developed by CareDx for patients looking to manage their health before and after a transplant, has now launched on Android. AlloCare is an easy-to-use mobile app designed to help organ transplant patients manage their health throughout the pre to post transplant journey with their mobile device. AlloCare allows patients to manage medications, schedule lab appointments, and view test results. Additionally, the app monitors biometrics and provides a platform for community engagement. With the launch on Android, the total addressable user base doubles. Users can download the app in the iOS or Android app stores now.
Fundamental Summary
The financials published by CareDx for Q1 were weak and discouraging. Their growth and value factors indicate a poor execution and strategy, which isn't generating exciting growth. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. We gave CareDx a 54 rating and a UNDERPERFORM recommendation.
CareDx reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 79.42 million compared to USD 67.4 million a year ago. Net loss was USD 19.65 million compared to USD 0.687 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.37 compared to USD 0.01 a year ago.
Business Description
CareDx. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Sector Overview
CareDx is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. CareDx's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -10.7 | -29.5% | 82 | |
| Net Cashflow | -137.5 | -164.3% | 98 | |
| Capital Expenditure | -20.8 | -53.2% | 40 | |
| Asset Turnover | 0.6 | -10.6% | 50 | |
| Free Cashflow | -0.6 | 16.0% | 84 |
* All values are TTM
The below chart reflects CareDx's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While CareDx's peer average final assessment score stands on 61.0, CareDx's score is 54.
- CDNA
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. CareDx's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), CareDx's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 31.
5D MA
22.99
50D MA
26.02
200D MA
41.67
MACD
-1.1
RSI
46.82
STOCH
23.91
Balance Sheet Analysis
CareDx's recently published balance sheet showed overall, underwhelming numbers. Both Cash & Equivalents and Book Value Factors were particularly concerning. CareDx's management did a relatively poor job managing cash and cash equivalents, which now sit at 171.9 and represents a -50.7% change from the last reporting period. Their anemic growth in cash and cash equivalents, specifically in contrast to their industry peers' performance, should hurt their stock price. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their cash and cash equivalents with a score of 39. Also, CareDx publishes discouraging results related to book value factors in this report. As of the current filing, price to book ratio (P/B) was reported as 2.4, representing a -53.9% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. Their book value factor metrics are even more concerning when compared to their peers. Therefore, their book value factors earned a score of 51. However, we can draw some encouragement from CareDx's momentum in Assets generation. The company's assets section could set high expectations for CareDx's future attractiveness, as they went to 546.7, which is a -3.5% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Consequently, their asset movement received a grade of 67. Consequently, their balance sheet earned a rank of 52.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 546.7 | -3.5% | 67 |
| Liabilities | 89.2 | -11.5% | 54 |
| Price to Book | 2.4 | -53.9% | 51 |
| Cash & Equivalents | 171.9 | -50.7% | 39 |
| Equity | 457.5 | -1.8% | 52 |
The below chart describes CareDx's performance as reflected on its balance sheet with respect to its peers. While CareDx received a balance sheet score of 52, the average of its peers stands on 63.0.
- CDNA
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 0 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 2 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 4 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 5 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 6 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 7 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 8 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 9 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 10 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 11 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 16 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 18 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 22 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 26 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 27 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 28 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 30 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 40 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 42 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 44 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 47 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 57 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 73 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 74 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 75 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 94 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
CareDx's most recent income statement report was not encouraging. CareDx's EBIDTA now sits at -32.2 and represents -116.3% change from the last reporting period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. Their EBITDA metrics are even more problematic when compared to their peers. Its EBITDA movement, therefore, received a grade of 44. Also, CareDx reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 308.4 and represented 4.1% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. As a result, their revenue efficiency earned a score of 61. However, one encouraging metric, Return Factors, stood out. In this filing, CareDx reported a return on equity (ROE) ratio of -10.7, which represents a change of -29.5%. Its return factor metrics are even more remarkable when compared to their peers. Consequently, their return factors received a grade of 82. Therefore, it received a cautionary score of 50.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -32.2 | -116.3% | 44 |
| Total Revenues | 308.4 | 4.1% | 61 |
| Return on Equity | -10.7 | -29.5% | 82 |
The below chart describes CareDx's performance as reflected on its income statement with respect to its peers. While CareDx received a income statement score of 50 , the average of its peers stands on 60.0.
- CDNA
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 0 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 2 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 4 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 5 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 6 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 7 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 8 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 9 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 10 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 11 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 16 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 18 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 22 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 26 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 27 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 28 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 30 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 40 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 42 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 47 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 73 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 74 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 94 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
CareDx appears likely to maintain its strong cash flow metrics and momentum going forward. CareDx presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -137.5, which is a change of -164.3% from the last filing. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. Consequently, their net cash flow movement received a grade of 98. Also, Free cash flow numbers published by CareDx were -0.6, which was a 16.0% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. Therefore, its free cash flow movement earned a score of 84. On the other hand, Capital Expenditure, jumped out as looking rather underwhelming. CareDx's management did not a remarkable job this period managing capital expenditures (CapEx). In terms of the raw numbers, CapEx was reported as -20.8, which represents a -53.2% change from the last period. The company's disappointing CapEx growth is expected to stunt the momentum they hoped for this period. Its CapEx movement, therefore, received a grade of 40. Because the company's management is doing an excellent job managing these critical metrics, the cash flow was given a score of 86.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -137.5 | -164.3% | 98 |
| Capital Expenditure | -20.8 | -53.2% | 40 |
| Asset Turnover | 0.6 | -10.6% | 50 |
| Free Cashflow | -0.6 | 16.0% | 84 |
The below chart describes CareDx's performance as reflected on its cash flow with respect to its peers. While CareDx received a cash flow score of 86, the average of its peers stands on 71.0.
- CDNA
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 0 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 2 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 4 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 5 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 6 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 7 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 8 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 9 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 10 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 11 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 16 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 18 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 22 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 26 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 27 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 28 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 30 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 40 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 42 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 47 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 73 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 74 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 94 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.